

May 16, 2012 Prior Authorization Advisory Committee Meeting

Division of Health Care Access and Accountability

Public Testimony Guidelines

Attention: Speakers will be limited to four minutes.

1. Speakers are required to submit a request to speak prior to the meeting. Please email DHSWIPDL@Wisconsin.gov to reserve a time slot. Speaking requests will be accepted beginning April 6, 2012.
 - When submitting a request to speak, please indicate on which drug you will focus your testimony.
 - Also include all drugs for which you intend to provide testimony.
2. Speakers must complete the Wisconsin Medicaid Pharmacy Prior Authorization Committee Presenter/Witness Disclosure form. This form will be emailed to you with your approximate speaking time.
3. Speakers must sign in upon arrival at the meeting at the registration table. Speakers must submit their completed and signed Presenter/Witness Disclosure form to staff prior to being allowed to speak. The forms will also be available at the registration table.
4. If a speaker with an assigned time slot is unable to testify, the speaker must email DHSWIPDL@Wisconsin.gov prior to the meeting. If they have asked someone to speak in their place, that person should be identified in the communication.
5. Prior Authorization Committee members have asked that manufacturers' or their representatives' testimony include the following information:
 - What new information has become available about the drug since the last review?
 - Have any head-to-head studies been completed and published in peer reviewed medical journals that demonstrate superiority of your product within the class?
6. Should all slots for spoken testimony become filled, written testimony may be submitted for review and consideration by the Committee. Written testimony must be emailed to DHSWIPDL@Wisconsin.gov. Written testimony must be received by April 27, 2012 to ensure time for committee members to review.
7. A speaker's waiting list will be kept and speakers will be allotted time to speak, in the order speaking requests were received, only if cancellations occur.
8. Multiple speakers per company or organization will be permitted within the same four minute time slot.
9. Speakers will be required to state their name, address, organization represented and the drug name(s) and class (es) applicable to their testimony.
10. Speakers will **NOT** be permitted to use audio/visual equipment during their presentation.
11. Speakers will **NOT** be permitted to provide handouts or demonstrate the devices used to administer their products to Committee members prior to, during, or after the meeting.

12. Time will be allotted for PA Committee members to ask questions of the speakers after testimony has been heard on each drug class.
13. Beginning April 16, 2012 through June 15, 2012, State staff and their contractors will not meet with manufacturers in order to prepare for and complete work associated with the meeting.

Clinical information regarding the drug classes will be discussed during public testimony. Even if no testimony is provided in a drug class, the PA Committee may still ask questions of the manufacturers or their representatives in the audience.

Drug classes will be reviewed in the order presented on the agenda.